ReviewKidney international2015
Do kidney stone formers have a kidney disease?
Review in Kidney international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement.Journal of nephrology · 2016Guideline
- Citrate-coated Prussian blue nanozyme hitchhikes neutrophils to ameliorate calcium oxalate crystal-induced kidney injury via inhibiting pyroptosis and NETosis.Journal of nanobiotechnology · 2026Article
- Analysis of 33,616 urinary stone cases: novel findings on renal transplantation impact, comorbidity profiles, and composition patterns.Frontiers in immunology · 2026Observational
- Article
- Early Detection and Monitoring of Nephrolithiasis: The Potential of Electrochemical Sensors.Sensors (Basel, Switzerland) · 2025Review
- UHRF1 promotes calcium oxalate-induced renal fibrosis by renal lipid deposition via bridging AMPK dephosphorylation.Cell biology and toxicology · 2025Article
- Targeting the NLRP3 inflammasome for calcium oxalate stones: pathophysiology and emerging pharmacological interventions.Frontiers in physiology · 2025Review
- Healthy dietary patterns, biological aging, and kidney stones: evidence from NHANES 2007-2018.Frontiers in nutrition · 2025Article
- Suppression of renal crystal formation, inflammation, and fibrosis by blocking oncostatin M receptor β signaling.Scientific reports · 2024Article
- Surgical procedure and recurrence of upper urinary tract stone: a national-wide study based on hospitalized patients.World journal of urology · 2024Article
- YAP/ACSL4 Pathway-Mediated Ferroptosis Promotes Renal Fibrosis in the Presence of Kidney Stones.Biomedicines · 2023Article
- Deep Segmentation Networks for Segmenting Kidneys and Detecting Kidney Stones in Unenhanced Abdominal CT Images.Diagnostics (Basel, Switzerland) · 2022Article
- Genetic testing enables a precision medicine approach for nephrolithiasis and nephrocalcinosis in pediatrics: a single-center cohort.Molecular genetics and genomics : MGG · 2022Article
- Cystinuria: An Overview of Diagnosis and Medical Management.Turkish archives of pediatrics · 2022Article
- Kidney Stones, Proteinuria and Renal Tubular Metabolic Acidosis: What Is the Link?Healthcare (Basel, Switzerland) · 2022Article
- Osteopontin: An important protein in the formation of kidney stones.Frontiers in pharmacology · 2022Review
- Women and other risk factors for chronic kidney disease of unknown etiology in Thailand: National Health Examination V Survey.Scientific reports · 2021Article
- Rosiglitazone Suppresses Renal Crystal Deposition by Ameliorating Tubular Injury Resulted from Oxidative Stress and Inflammatory Response via Promoting the Nrf2/HO-1 Pathway and Shifting Macrophage Polarization.Oxidative medicine and cellular longevity · 2021Article
- Amelioration of lithiatic injury to renal tissue by candesartan and sodium thiosulfate in a rat model of nephrolithiasis.PloS one · 2021Article
- Impact of potassium citrate on urinary risk profile, glucose and lipid metabolism of kidney stone formers in Switzerland.Clinical kidney journal · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Nephrolithiasis is a highly prevalent disorder affecting approximately one in eleven people and is associated with multiple complications including hypertension, cardiovascular disease, and chronic kidney disease. Significant epidemiologic associations with chronic kidney disease and ESRD have been noted and are reviewed herein, but debate persists in the literature as to whether kidney stone formation is a pathogenic process contributing to kidney disease. Corroborating evidence supporting the presence of kidney disease in stone formers includes the variability of renal function by stone type, the positive association of stone size with renal dysfunction, the presence of markers of renal injury in the urine of even asymptomatic stone formers, and direct evidence of renal tissue injury on histopathology. Proposed pathogenic mechanisms include recurrent obstruction and comorbid conditions such as recurrent urinary tract infections and structural abnormalities. Recent work evaluating the renal histopathology of different groups of stone formers adds further granularity, suggesting variability in mechanisms of renal injury by stone type and confirming the pathogenic effects of crystal formation. Genetic abnormalities leading to stone formation including cystinuria and primary hyperoxaluria, among others, contribute to the burden of disease in the stone-forming population.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.